Literature DB >> 20805529

Immune reconstitution inflammatory syndrome after withdrawal of natalizumab?

T Lenhard1, A Biller, W Mueller, I Metz, J Schönberger, B Wildemann.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20805529     DOI： 10.1212/WNL.0b013e3181f07362

Source DB:  PubMed          Journal:  Neurology        ISSN： 0028-3878            Impact factor:   9.910


× No keyword cloud information.
  16 in total

1.  [Immune reconstitution syndrome].

Authors:  D Meyer-Olson; D Ernst; M Stoll
Journal:  Z Rheumatol       Date:  2012-04       Impact factor: 1.372

2.  Post-natalizumab clinical and radiological findings in a cohort of multiple sclerosis patients: 12-month follow-up.

Authors:  Marta Melis; Eleonora Cocco; Jessica Frau; Lorena Lorefice; Giuseppe Fenu; Giancarlo Coghe; Marco Mura; Maria Giovanna Marrosu
Journal:  Neurol Sci       Date:  2013-08-30       Impact factor: 3.307

3.  Natalizumab-associated progressive multifocal leukoencephalopathy in a patient with multiple sclerosis: a postmortem study.

Authors:  Christian Wüthrich; Bogdan F Gh Popescu; Sarah Gheuens; Michael Marvi; Ronald Ziman; Stephen Pojen Denq; Mylyne Tham; Elizabeth Norton; Joseph E Parisi; Xin Dang; Claudia F Lucchinetti; Igor J Koralnik
Journal:  J Neuropathol Exp Neurol       Date:  2013-11       Impact factor: 3.685

4.  Intense immunosuppression for the treatment of an immune reconstitution inflammatory syndrome-like exacerbation after natalizumab withdrawal: a case report.

Authors:  Maria Sepúlveda; Sara Llufriu; Yolanda Blanco; Nuria Solà-Valls; Delon La Puma; Joan Berenguer; Pablo Villoslada; Albert Saiz
Journal:  J Neurol       Date:  2014-11-20       Impact factor: 4.849

5.  Pulsed steroids followed by glatiramer acetate to prevent inflammatory activity after cessation of natalizumab therapy: a prospective, 6-month observational study.

Authors:  María José Magraner; Francisco Coret; Arantxa Navarré; Isabel Boscá; María Simó; Matilde Escutia; Ana Bernad; Laura Navarro; Bonaventura Casanova
Journal:  J Neurol       Date:  2011-04-06       Impact factor: 4.849

6.  Radiologic MS disease activity during natalizumab treatment interruption: findings from RESTORE.

Authors:  Michael Kaufman; Bruce A C Cree; Jerome De Sèze; Robert J Fox; Ralf Gold; Hans-Peter Hartung; Douglas Jeffery; Ludwig Kappos; Xavier Montalbán; Bianca Weinstock-Guttman; Barry Ticho; Petra Duda; Amy Pace; Denise Campagnolo
Journal:  J Neurol       Date:  2014-11-09       Impact factor: 4.849

7.  De-escalation from natalizumab in multiple sclerosis: recurrence of disease activity despite switching to glatiramer acetate.

Authors:  Joachim Havla; Lisa Ann Gerdes; Ingrid Meinl; Markus Krumbholz; Hans Faber; Frank Weber; Hannah Luise Pellkofer; Reinhard Hohlfeld; Tania Kümpfel
Journal:  J Neurol       Date:  2011-03-23       Impact factor: 4.849

Review 8.  Therapeutic decisions in multiple sclerosis: moving beyond efficacy.

Authors:  Wolfgang Brück; Raff Gold; Brett T Lund; Celia Oreja-Guevara; Alexandre Prat; Collin M Spencer; Lawrence Steinman; Mar Tintoré; Timothy L Vollmer; Martin S Weber; Leslie P Weiner; Tjalf Ziemssen; Scott S Zamvil
Journal:  JAMA Neurol       Date:  2013-10       Impact factor: 18.302

9.  Acute Inflammatory Optic Neuritis Associated with a Self-Taper of Oral Prednisone in a Patient Taking Adalimumab.

Authors:  Abhinav Komandur; Peter MacIntosh; Heather Moss
Journal:  Neuroophthalmology       Date:  2019-01-18

Review 10.  The CD8 T Cell-Epstein-Barr Virus-B Cell Trialogue: A Central Issue in Multiple Sclerosis Pathogenesis.

Authors:  Caterina Veroni; Francesca Aloisi
Journal:  Front Immunol       Date:  2021-07-07       Impact factor: 7.561
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.